CDTX (Cidara) Projected Price to Earnings

Official company branding of Cidara Therapeutics (CDTX)

Cidara Therapeutics (CDTX) focuses on advanced R&D in the field of antiviral immunotherapy. The team is developing breakthrough conjugates to shift infection prevention standards. The projected P/E valuation visualizes the business's market value, where 0.00 serves as the current metric level. Cloudbreak technology enables the creation of long-acting drugs, simplifying the treatment of severe diseases.

CDTX - Cidara Therapeutics Corp Market Cap to Projected Earnings over the range 07/04/2022 - 01/17/2026

Analytical breakdowns for Cidara Therapeutics

- current price and projected stock value:
Stock Quotes Cidara Therapeutics|CDTX - Fair Value Consensus
- business market valuation indicators:
Market Valuation Cidara Corp|CDTX - Total Company Value
- issuer book value statistics:
Book Value per Share Cidara|CDTX - Book Valuation of Business|Market Value to Book Value Ratio cidara.com|CDTX - Aggregate Asset Value
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Cidara Therapeutics|CDTX - Long-Term Debt to Capital|Short-Term Debt to Equity Cidara Therapeutics Inc|CDTX - Company Total Debt Obligations|Debts to Book Capitalization Cidara|CDTX - Company Long-Term Liabilities|Company Short-Term Debts Cidara|Quick Ratio cidara.com
- earnings and market ratios statistics:
CDTX - Company Profit|Projected Future Earnings Cidara Therapeutics|CDTX - P/E Multiple|Future Price to Earnings Cidara Corp|CDTX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Cidara Therapeutics Corp|CDTX - Operating profit EBITDA|Net earnings per share for the last 12 months Cidara|CDTX - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months cidara.com|CDTX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Cidara Therapeutics
- revenue and sales proceeds data:
CDTX - Company Sales Revenue|Projected Sales Volume Cidara Corp|CDTX - Price to Sales|Price-to-Projected Revenue Ratio Cidara|CDTX - Revenue Dynamics YoY (Last Twelve Months)
Basic company analysis:Cidara Therapeutics
Product sample of Cidara

Market expectations for Cidara Therapeutics (CDTX) often precede current financial results. The company's forward P/E ratio is calculated by dividing the market price per share by the expected net income of future periods. This indicator allows for an assessment of the premium paid for future growth. The stability of this metric is supported by long-term raw material procurement for drug production, which minimizes operational risks and ensures the sustainability of the biotech business's profitability.

Competitors of Cidara Therapeutics

Projected Price to Earnings GILD (Gilead Sciences Inc)|NVAX (Novavax, Inc.) - Future Price to Earnings Multiple|CureVac N.V. - Projected Price to Earnings|Valneva SE - Future Price to Earnings|VIR - Future Price to Earnings|Market Cap to Projected Earnings SIGA Technologies Inc SIGA|EBS (Emergent BioSolutions Inc) - Projected Price to Earnings|Atea Pharmaceuticals - Future Price to Earnings Multiple|Projected Price to Earnings IVVD|Forward P/E Multiple enanta.com|Forward P/E Multiple INO|Market Cap to Projected Earnings HilleVax|Future Price to Earnings Kalaris Therapeutics Inc. KLRS|DYAI: Price to Future Earnings Ratio|NanoViricides, Inc. - Forward P/E Multiple|TLPH - Forward P/E Multiple|COCP: Forward P/E Multiple|Traws Pharma, Inc. (TRAW) - Forward P/E Multiple|Projected Price to Earnings DWTX|Future Price to Earnings QLGN|Projected Price to Earnings ALVR (AlloVir)|Future Price to Earnings VBIV (VBI Vaccines)|Future Price to Earnings virios.com VIRI|Market Cap to Future Earnings Ratio VXRT (vaxart.com)